Filtered By:
Cancer: Hepatocellular Carcinoma

This page shows you your search results in order of date. This dataset has been filtered by: Psychiatry & Psychology, . You may remove the filter by clicking on the Remove Filter tab.

Order by Relevance | Date

Total 2920 results found since Jan 2013.

Identification and validation of a fatty acid metabolism gene signature for the promotion of metastasis in liver cancer
Oncol Lett. 2023 Sep 6;26(4):457. doi: 10.3892/ol.2023.14044. eCollection 2023 Oct.ABSTRACTMetastasis is a fatal status for liver cancer, and the identification of an effective prediction model and promising therapeutic target is essential. Given the known relationship between fatty acid (FA) metabolism and the liver, the present study aimed to investigate dysregulation of genes associated with FA metabolism in liver cancer. Bioinformatics analyses were performed on data from patients with hepatocellular carcinoma (HCC) obtained from The Cancer Genome Atlas database using R software packages. Online public tools such as th...
Source: Oncology Letters - September 22, 2023 Category: Cancer & Oncology Authors: Zhenshan Zhang Jun Sun Chao Jin Likun Zhang Leilei Wu Gendong Tian Source Type: research

MicroRNAs and their vital role in apoptosis in hepatocellular carcinoma: miRNA-based diagnostic and treatment methods
Gene. 2023 Sep 14;888:147803. doi: 10.1016/j.gene.2023.147803. Online ahead of print.ABSTRACTHepatocellular carcinoma (HCC) is one of the most prevalent malignancies with high invasive and metastatic capability. Although significant advances have been made in the treatment of HCC, the overall survival rate of patients is still low. It is essential to explore accurate biomarkers for early diagnosis and prognosis along with therapeutic procedures to increase the survival rate of these patients. Anticancer therapies can contribute to induce apoptosis for the elimination of cancerous cells. However, dysregulated apoptosis and ...
Source: Gene - September 16, 2023 Category: Genetics & Stem Cells Authors: Masoumeh Hajizadeh Farnaz Hajizadeh Sevil Ghaffarei Mohammad Amin Doustvandi Khadijeh Hajizadeh Seyyed Mohammad Yaghoubi Fateme Mohammadnejad Nadia Allahyarzadeh Khiabani Pegah Mousavi Behzad Baradaran Source Type: research

MicroRNAs and their vital role in Apoptosis in Hepatocellular carcinoma: miRNA-based diagnostic and treatment methods
Gene. 2023 Sep 14:147803. doi: 10.1016/j.gene.2023.147803. Online ahead of print.ABSTRACTHepatocellular carcinoma (HCC) is one of the most prevalent malignancies with high invasive and metastatic capability. Although significant advances have been made in the treatment of HCC, the overall survival rate of patients is still low. It is essential to explore accurate biomarkers for early diagnosis and prognosis along with therapeutic procedures to increase the survival rate of these patients. Anticancer therapies can contribute to induce apoptosis for the elimination of cancerous cells. However, dysregulated apoptosis and prol...
Source: Gene - September 16, 2023 Category: Genetics & Stem Cells Authors: Masoumeh Hajizadeh Farnaz Hajizadeh Sevil Ghaffarei Mohammad Amin Doustvandi Khadijeh Hajizadeh Seyyed Mohammad Yaghoubi Fateme Mohammadnejad Nadia Allahyarzadeh Khiabani Pegah Mousavi Behzad Baradaran Source Type: research

Deep dissection of stemness-related hierarchies in hepatocellular carcinoma
Increasing evidence suggests that hepatocellular carcinoma (HCC) stem cells (LCSCs) play an essential part in HCC recurrence, metastasis, and chemotherapy and radiotherapy resistance. Multiple studies have dem...
Source: Journal of Translational Medicine - September 16, 2023 Category: Research Authors: Rui Liang, Weifeng Hong, Yang Zhang, Di Ma, Jinwei Li, Yisong Shi, Qing Luo, Shisuo Du and Guanbin Song Tags: Research Source Type: research

Improving diverse participation in cancer clinical trials
Trans Am Clin Climatol Assoc. 2023;133:149-156.ABSTRACTDespite significant improvement in overall cancer mortality (>30% since 1991), these survival benefits have not been experienced by all groups uniformly especially in those of diverse heritage. Drivers of cancer health inequity are multi-factorial including more adverse social determinants of health, later stage cancer presentation, decreased health care access, decreased health literacy, and cultural barriers to prompt cancer care. Adding to these disparities is the historical inclusion of primarily well-insured Caucasian patients into cancer clinical trials leadin...
Source: Transactions of the American Clinical and Climatological Association - September 13, 2023 Category: General Medicine Authors: Ruben Mesa Rebecca T Jones Source Type: research

Improving diverse participation in cancer clinical trials
Trans Am Clin Climatol Assoc. 2023;133:149-156.ABSTRACTDespite significant improvement in overall cancer mortality (>30% since 1991), these survival benefits have not been experienced by all groups uniformly especially in those of diverse heritage. Drivers of cancer health inequity are multi-factorial including more adverse social determinants of health, later stage cancer presentation, decreased health care access, decreased health literacy, and cultural barriers to prompt cancer care. Adding to these disparities is the historical inclusion of primarily well-insured Caucasian patients into cancer clinical trials leadin...
Source: Transactions of the American Clinical and Climatological Association - September 13, 2023 Category: General Medicine Authors: Ruben Mesa Rebecca T Jones Source Type: research

Improving diverse participation in cancer clinical trials
Trans Am Clin Climatol Assoc. 2023;133:149-156.ABSTRACTDespite significant improvement in overall cancer mortality (>30% since 1991), these survival benefits have not been experienced by all groups uniformly especially in those of diverse heritage. Drivers of cancer health inequity are multi-factorial including more adverse social determinants of health, later stage cancer presentation, decreased health care access, decreased health literacy, and cultural barriers to prompt cancer care. Adding to these disparities is the historical inclusion of primarily well-insured Caucasian patients into cancer clinical trials leadin...
Source: Transactions of the American Clinical and Climatological Association - September 13, 2023 Category: General Medicine Authors: Ruben Mesa Rebecca T Jones Source Type: research

Improving diverse participation in cancer clinical trials
Trans Am Clin Climatol Assoc. 2023;133:149-156.ABSTRACTDespite significant improvement in overall cancer mortality (>30% since 1991), these survival benefits have not been experienced by all groups uniformly especially in those of diverse heritage. Drivers of cancer health inequity are multi-factorial including more adverse social determinants of health, later stage cancer presentation, decreased health care access, decreased health literacy, and cultural barriers to prompt cancer care. Adding to these disparities is the historical inclusion of primarily well-insured Caucasian patients into cancer clinical trials leadin...
Source: Transactions of the American Clinical and Climatological Association - September 13, 2023 Category: General Medicine Authors: Ruben Mesa Rebecca T Jones Source Type: research

Improving diverse participation in cancer clinical trials
Trans Am Clin Climatol Assoc. 2023;133:149-156.ABSTRACTDespite significant improvement in overall cancer mortality (>30% since 1991), these survival benefits have not been experienced by all groups uniformly especially in those of diverse heritage. Drivers of cancer health inequity are multi-factorial including more adverse social determinants of health, later stage cancer presentation, decreased health care access, decreased health literacy, and cultural barriers to prompt cancer care. Adding to these disparities is the historical inclusion of primarily well-insured Caucasian patients into cancer clinical trials leadin...
Source: Clinical Prostate Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Ruben Mesa Rebecca T Jones Source Type: research

Improving diverse participation in cancer clinical trials
Trans Am Clin Climatol Assoc. 2023;133:149-156.ABSTRACTDespite significant improvement in overall cancer mortality (>30% since 1991), these survival benefits have not been experienced by all groups uniformly especially in those of diverse heritage. Drivers of cancer health inequity are multi-factorial including more adverse social determinants of health, later stage cancer presentation, decreased health care access, decreased health literacy, and cultural barriers to prompt cancer care. Adding to these disparities is the historical inclusion of primarily well-insured Caucasian patients into cancer clinical trials leadin...
Source: Transactions of the American Clinical and Climatological Association - September 13, 2023 Category: General Medicine Authors: Ruben Mesa Rebecca T Jones Source Type: research

Improving diverse participation in cancer clinical trials
Trans Am Clin Climatol Assoc. 2023;133:149-156.ABSTRACTDespite significant improvement in overall cancer mortality (>30% since 1991), these survival benefits have not been experienced by all groups uniformly especially in those of diverse heritage. Drivers of cancer health inequity are multi-factorial including more adverse social determinants of health, later stage cancer presentation, decreased health care access, decreased health literacy, and cultural barriers to prompt cancer care. Adding to these disparities is the historical inclusion of primarily well-insured Caucasian patients into cancer clinical trials leadin...
Source: Transactions of the American Clinical and Climatological Association - September 13, 2023 Category: General Medicine Authors: Ruben Mesa Rebecca T Jones Source Type: research

Improving diverse participation in cancer clinical trials
Trans Am Clin Climatol Assoc. 2023;133:149-156.ABSTRACTDespite significant improvement in overall cancer mortality (>30% since 1991), these survival benefits have not been experienced by all groups uniformly especially in those of diverse heritage. Drivers of cancer health inequity are multi-factorial including more adverse social determinants of health, later stage cancer presentation, decreased health care access, decreased health literacy, and cultural barriers to prompt cancer care. Adding to these disparities is the historical inclusion of primarily well-insured Caucasian patients into cancer clinical trials leadin...
Source: Transactions of the American Clinical and Climatological Association - September 13, 2023 Category: General Medicine Authors: Ruben Mesa Rebecca T Jones Source Type: research

Improving diverse participation in cancer clinical trials
Trans Am Clin Climatol Assoc. 2023;133:149-156.ABSTRACTDespite significant improvement in overall cancer mortality (>30% since 1991), these survival benefits have not been experienced by all groups uniformly especially in those of diverse heritage. Drivers of cancer health inequity are multi-factorial including more adverse social determinants of health, later stage cancer presentation, decreased health care access, decreased health literacy, and cultural barriers to prompt cancer care. Adding to these disparities is the historical inclusion of primarily well-insured Caucasian patients into cancer clinical trials leadin...
Source: Clinical Prostate Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Ruben Mesa Rebecca T Jones Source Type: research

MicroRNA-223: a key regulator of liver tumour microenvironment
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide with few effective drug treatments. Recent combination therapies inhibiting immune checkpoints and angiogenesis showed better overall and progression-free survival outcomes than the protein kinase inhibitor sorafenib in patients with unresectable HCC,1 suggesting targeting tumour microenvironment (TME) is a promising strategy for the treatment of HCC. However, how the TME is developed and regulated is still poorly known. Thus, understanding the pathogenesis of HCC TME would be essential in order to develop more effective HCC thera...
Source: Gut - September 13, 2023 Category: Gastroenterology Authors: Avila, M. A. Tags: Gut Commentary Source Type: research

Multiparametric MRI ‐based model for prediction of local progression of hepatocellular carcinoma after thermal ablation
ConclusionsThe DLRMM model is essential to identify LTP risk of HCC patients who underwent TA and may potentially benefit personalized decision-making.
Source: Cancer Medicine - September 11, 2023 Category: Cancer & Oncology Authors: Chao Chen, Qiuying Han, He Ren, Siyi Wu, Yangyang Li, Jiandong Guo, Xinghai Li, Xiang Liu, Chengzhi Li, Yunfei Tian Tags: RESEARCH ARTICLE Source Type: research